Prevention treatment for hemophilia A with joint swelling
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a preventive treatment called efanesoctocog alfa to see if it can help people with moderate to severe hemophilia A who have joint swelling (synovial hypertrophy). It aims to reduce joint bleeding and improve joint health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old.
- You have moderate to severe hemophilia A, meaning your body makes very little or no factor VIII.
- You have at least one joint with swelling (synovial hypertrophy), confirmed by an ultrasound.
- You have been using preventive treatment (prophylaxis) for hemophilia in the last 12 months.
- You do not have a factor VIII inhibitor (a substance that blocks treatment), and you have not had immune tolerance therapy in the last 2 years.
- If you are a woman who could become pregnant, you must not be pregnant or breastfeeding and agree to use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
This study tests a new medicine called SKP-0141 to see if it can safely treat and prevent bleeding in people with severe hemophilia A. It might help reduce the number of bleeds and improve quality of life.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
Hear when a new Factor VIII Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.